Høgdall E, Fung ET, Christensen IJ, Yip C, Nedergaard L, Engelholm SA, Risum S, Petri AL, Lundvall L, Lomas L, Høgdall C. Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients.
Proteomics Clin Appl 2011;
4:940-52. [PMID:
21137034 DOI:
10.1002/prca.200900171]
[Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
PURPOSE
To determine if the level of apolipoprotein A1, hepcidin, transferrin, inter-α trypsin IV internal fragment, transthyretin (TT), connective-tissue activating protein 3 (CTAP3), serum amyloid A1, β-2 microglobulin (B2M) might have impact on overall and progression-free survival for ovarian cancer (OC) patients.
EXPERIMENTAL DESIGN
Serum from 150 OC patients was tested using SELDI-TOF-MS.
RESULTS
A proteomic prognostic index (xb-pro) was constructed using the regression coefficients based on inter-α trypsin IV internal fragment, B2M and TT. A multivariable Cox survival analysis including the xb-pro index showed that xb-pro (p<0.0001, HR=2.50, 95% CI: 1.65-3.79), residual tumor after primary surgery (p=0.0005), age (p=0.01) and chemotherapy (p=0.0002) are of independent prognostic value for overall survival. International Federation of Gynecology and Obstetrics stage, performance status, histological type of tumor and serum CA125 were found of no independent value. A proteomic index (xb-pfs) based on B2M and CTAP3 was found to predict progression-free survival (xb-pfs: p=0.008, HR=1.77, 95% CI: 1.17-2.70 together with type of surgery, age and chemotherapy.
CONCLUSIONS AND CLINICAL RELEVANCE
We found an index with three proteomic biomarkers (xb-pro) to be of independent prognostic value for overall survival and an index with two proteomic biomarkers (xb-pfs) with evidence of independent prognostic value for progression-free survival.
Collapse